cabazitaxel
cabazitaxel: sourced relationships with 1 company · 15 clinical trials tracked · 1 FDA decision.
cabazitaxel evidence translation
What we can confirm
1 FDA record · 15 tracked trials
What it means
What to watch
Prepared research question
How could cabazitaxel → SNY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 3 study sponsors
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Sanofi (SNY) Reported 2010-06-17 · Current development: unknownSource | Approved |
| Sanofi (SNY) Reported 2010-06-17 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (15)showing 10 most recent
A Randomized Phase II/III Trial Evaluating Bipolar Androgen Therapy Followed by Darolutamide vs. Standard of Care in Patients With Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Second progression-free survival (PFS2) (Phase II)
A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Primary endpoint: Radiographic Progression-Free Survival (rPFS)
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Primary endpoint: OS
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Primary endpoint: Objective Response
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
Primary endpoint: Overall Survival (OS)
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Primary endpoint: Number of participants who experience one or more dose-limiting toxicities (DLTs)
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
Primary endpoint: Part 1: Number of Participants With Dose Limiting Toxicity (DLT)
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
Primary endpoint: Body Mass Index (BMI)
A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
Primary endpoint: Proportion of subjects who are progression-free and alive (progression-free survival) at 6 months
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Primary endpoint: Progression-free Survival (PFS)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with cabazitaxel?
cabazitaxel has dated SEC/FDA relationship records for Sanofi.
How many clinical trials involve cabazitaxel?
BioSniper tracks 15 clinical trials involving cabazitaxel.
What is cabazitaxel's latest FDA decision?
The most recent tracked FDA decision for cabazitaxel is Approval for 1 INDICATIONS AND USAGE JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 ), dated June 17, 2010.